Alexander Anderson
Has grant
Department Chair
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Cancer as a Complex Adaptive System
Open Date: 2015-09-23
Close Date: 2020-08-31
Grant: Close
Predicting Prostate Cancer Aggressiveness
Open Date: 2011-09-14
Close Date: 2016-08-31
Grant: Close
Guidance cues and pattern prediction in the developing retinal vasculature: a combined experimental and theoretical modelling approach
Open Date: 2008-06-30
Close Date: 2011-06-29
Articles (36)
Year:
2026
Year:
2026
Multiplexed imaging of tissues is an approach that holds promise for improving early detection, diagnosis, and treatment of cancer. Here, we investigated multiplexed histological images of paired pre- and on-treatment samples from nine patients with immunotherapy-refractory non-small cell lung cancer (NSCLC) treated with an oral HDAC inhibitor (vorinostat) combined with a PD-1 inhibitor (pembrolizumab). Patient responses comprised of either stable disease (SD) or progressive disease (PD). An extensive multiplexed-image analysis pipeline involving both cell segmentation and quadrats, coupled with spatial statistics, machine learning, and deep learning was built to analyze the spatial and temporal features that predict disease progression and identify potential clinical biomarkers. Distinct spatial immune ecologies existed between SD and PD patients, and tumors from PD patients were already characterized by an immune-suppressive environment prior to treatment. Finally, the learned spatial ecologies predicted disease progression better than PD-L1 status alone, suggesting these ecologies could be used as potential companion biomarkers with PD-L1 in NSCLC. These findings will be investigated in a larger-cohort study generated from an ongoing clinical trial (NCT02638090) that includes a wider range of responses including complete and partial responders. Together, this study developed a computational infrastructure for analyzing multiplex imaging to predict immunotherapy response in NSCLC, which can potentially be generalized to any type of cancer.
Year:
2026
Mathematics has long provided a quantitative framework to interpret cancer biology and treatment. Driven by richer biological and clinical data, the field has evolved into a multidisciplinary and translational endeavor - giving rise to Mathematical Oncology. Yet, the field’s strong interdisciplinarity obscures a comprehensive view of its evolution, as well as the boundaries between Mathematical Oncology and adjacent domains. Here, we address this gap through a comprehensive bibliometric analysis spanning 75 years of mathematical research in oncology. Using a manually curated corpus (∼1,500 papers) and a large query-based dataset (∼19,000 papers), we map the field’s conceptual and collaborative development over time. Independent analyses reveal sustained growth, high impact, and pronounced interdisciplinarity, together with a gradual shift from fundamental cancer biology toward therapeutic modeling. This reorientation underpins the emergence of Mathematical Oncology as a distinct field, separate from Systems Biology and Pharmacokinetics / Pharmacodynamics. We show how diverse concepts interlace within Mathematical Oncology, bridging applied mathematics, optimal control, evolutionary theory, and imaging. Collectively, we demonstrate that Mathematical Oncology is not merely the application of mathematics to cancer, but the use of interpretable models integrating clinical, biological, and physical knowledge to improve screening, understand disease evolution, guide therapy, and strengthen forecasting.
Year:
2026
Acquired resistance to targeted therapies is the primary barrier to durable cancer remission. Therapy resistance is often associated with stemness and intermediate EMT programs, which are often viewed as proximal resistance mechanisms. On the other hand, a growing body of evidence suggests that these programs facilitate resistance through plasticity-mediated adaptations. Integrating computational modeling, functional experimental assays, and lineage tracing, we investigated the relationship between EMT and therapy resistance in experimental models of acquired resistance to ALK+ lung cancer. Our results support a model where phenotypic plasticity, associated with intermediate EMT, is a selectable trait, and selection for subpopulations with higher phenotypic plasticity is amplified under a multifactorial resistance scenario. Consequently, resistance to targeted therapy is associated with higher ability to adapt to orthogonal therapeutic and environmental stressors, as well as higher metastatic potential. These findings identify cellular plasticity as the fundamental substrate from which multifactorial resistance and metastatic competence evolve, indicating that targeting phenotypic plasticity can suppress the acquisition of resistance and prolong therapeutic responses.
Year:
2026
Mathematical models have played a significant role in the development of current chemo- and radiotherapy treatment protocols. The widespread use of cytotoxic drugs has shaped the paradigm of uniformly administering a “maximum tolerated dose” to patients; however, this approach fails to account for the dynamic and heterogeneous nature of challenging cancers, including metastatic disease. Recent clinical trials and regulatory decisions have aimed to address these issues by integrating mathematical models to drive preclinical experiments and personalize treatment schedules. By capturing mechanisms of dose–response dynamics, ecological dynamics such as tumor–immune interactions or competition dynamics, and evolutionary dynamics across different therapeutic regimens, mathematical models hold the potential to advance current therapeutic strategies. As more preclinical and clinical data become available, the integration of mathematical models with “virtual patient” frameworks, including “digital twins,” and artificial intelligence methods could further advance the mechanistic complexity and decision support capabilities of such models. Nonetheless, translating mechanistic models to routine clinical workflows will require overcoming current translational barriers, notably access to clinical data in standardized formats and regulatory constraints. Overall, recent trials demonstrate the promise of the field of mathematical oncology in translating predictive dynamics into treatment decision-making beyond the “maximum tolerated dose” approach. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI .
Year:
2025
The development of de novo resistance is a major disadvantage in molecularly targeted therapies. While much focus is on cell-intrinsic mechanisms, the microenvironment is also known to play a crucial role. This study examines interactions between cancer cells and cancer associated fibroblasts (CAFs) to understand the local crosstalk facilitating residual disease. Using a hybrid-discrete-continuum model, we explore how treatment-induced stress responses can elicit CAF activation and how breaks in treatment allow microenvironment normalisation. We investigate how fluctuating environmental conditions shape the local crosstalk and ultimately drive residual disease. Our experimentally calibrated model identifies environmental and treatment conditions that allow tumour eradication and those that enable survival. We find two distinct mechanisms that underpin residual disease: vasculature-limited drug delivery and CAF-mediated rescue. This work provides a better understanding of the mechanisms that drive the creation of localised residual disease, crucial to informing the development of more effective treatment protocols.
Year:
2025
Accessibility of immune cells to the tumor microenvironment (TME) in many solid tumors can be influenced by extracellular matrix (ECM) deposition, organization, and remodeling within tumor stroma. Specifically, lysyl hydroxylase-2 (LH2)-catalyzed lysine hydroxylation in type-I collagen telopeptides leads to formation of intermolecular collagen cross-links creating a stiffened and proteolytically resistant, stable ECM. Advanced head and neck squamous cell carcinomas (HNSCC) frequently exhibit desmoplasia with elevated LH2 expression, and Immune-checkpoint (ICI) therapy is effective in only <20% patients, suggesting that ECM remodeling mechanistically governs the composition and function of TME infiltrates. We show that elevated LH2 and collagen alignment promotes stromal accumulation of CD8⁺ T-cells, and poor response to ICI in HPV-HNSCCs. Integration of clinical biopsies, transcriptomic datasets, and an immunocompetent syngeneic mouse model revealed that aligned collagen spatially restricts adhesion G protein–coupled receptor positive (ADGRG1⁺) CD8⁺ T-cells to activate a non-canonical GPCR-mediated mechanosensory program that drives dysfunction and exhaustion. Statement of significance: Desmoplasia is common in solid tumors, and immune checkpoint inhibitors benefit only some patients. Current biomarkers like PD-L1 and TMB have limited value. Our findings reveal a previously unrecognized collagen-ADGRG1 mechanosensory immune checkpoint, offering a clinically tractable, spatially resolved biomarker to better stratify patients for immunotherapy.
Year:
2025
Movies corresponding to simulation examples in Figure 5, comparing sequential seeding of homogeneous metastases with simultaneous seeding of heterogeneous metastases over simulations with different total burden and number of metastases.
Year:
2025
Serial low-dose computed tomography (LDCT) scans in patients who are diagnosed with lung cancer during screening offer a history of the densities of tumors and the tissues that surround them during carcinogenesis and cancer progression. We built a CT-scan resolution computational model to explore how variations in lung tissue density impact tumor growth and evolution in non-small cell lung cancer (NSCLC). Our findings indicate that tumors spread more rapidly through denser tissues when they upregulate glycolytic pathways and acid production, whilst tumors spread more rapidly through sparser tissues when they upregulate angiogenesis. We used data and images from the National Lung Screening Trial to calibrate our model for untreated lung cancer growth in patients and corroborated our findings in low-density environments. Significance Our lung lesion model supports prior studies that find tumors tend to “speciate” into angiogenic or glyoclytic phenotypes. We demonstrate that these evolutionary strategies may in part be driven by the surrounding normal tissue density. We also suggest predictive biomarkers of tumor phenotype so that these evolutionary strategies may be detected and targeted in patients.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (29)
Jose Alejandro Guevara-Patino
Professor
Moffitt Cancer Center
Berkley E. Gryder
Case Western Reserve University
Daria Miroshnychenko
H Lee Moffitt Cancer Center and Research Institute
Xuefeng Wang
Associate Member/Professor
H Lee Moffitt Cancer Center and Research Institute
David Basanta
Professor
Moffitt Cancer Center
Iain McNeish
Imperial College London
Cliona O'Farrelly
Professor of Comparative Immunology
Trinity College Dublin
Joshua Bull
Group Leader
The Francis Crick Institute
Antonio L Amelio
Senior Member
H Lee Moffitt Cancer Center and Research Institute
Carlo Maley
Professor
Arizona State University
Noemi Picco
Senior Lecturer
Swansea University College of Science
Andriy Marusyk
Associate member
H Lee Moffitt Cancer Center and Research Institute
Derek Park
H Lee Moffitt Cancer Center and Research Institute
Roger Li
H Lee Moffitt Cancer Center and Research Institute
Jose Conejo-Garcia
Duke Science and Technology Scholar
Duke Medicine
Philipp Altrock
Resarch Group Leader
University Hospital Schleswig-Holstein
Jacob Scott
Professor
University of Rochester
Sara Hamis
Assistant Professor
Uppsala University
Dhananjay Bhaskar
Assistant Professor
University of Wisconsin-Madison
Jeffrey West
Assistant Professor
University of South Florida
Matthew Schabath
Program Leader and Senior Member
H Lee Moffitt Cancer Center and Research Institute
Kit Gallagher
University of Oxford
Patrick Cosgrove
Staff Scientist
Beckman Research Institute, City of Hope
Paulo Rodriguez
Senior Member-Professor
H Lee Moffitt Cancer Center and Research Institute
J. Silvio Gutkind
Chair, Department of Pharmacology
University of California
Xiaoqing Yu
Associate Professor
H Lee Moffitt Cancer Center and Research Institute
Mark Robertson-Tessi
H Lee Moffitt Cancer Center and Research Institute
Marilyn Bui
Senior Member and Professor
H Lee Moffitt Cancer Center and Research Institute
Luis Cisneros
Assistant Research Professor
Mayo Clinic
Make your next move.
Prepare your application
Review drafts before you send them.